Reducing Risk in Residual Breast Cancer
About this video
Advanced · Editorial review · 85% confidencePicked one by one from a mixed channel. Transcript check: Detailed explanation of a clinical trial on trastuzumab emtansine for HER2-positive breast cancer, including methodology and results.. Channel rule: Include only these: clinical procedure and examination demonstration videos (Videos in Clinical Medicine style, e.g., biopsies, maneuvers, injections, exam signs like ataxia); animated or narrated research and mechanism explainers ('in 3 Minutes', Quick Take, Clinical Implications of Basic Research); and long-form medical history documentaries. Exclude all interviews, podcasts, weekly news roundups, roundtables and health-policy/management discussions.
A 2-minute video from NEJM Group: “Reducing Risk in Residual Breast Cancer”.
Video by NEJM Group, played through YouTube's embedded player.